Home / Market News / $ADXN
benzinga Corporate Catalyst Impact 95/100 ● negative

CORRECTION: Addex Therapeutics Q2 EPADS $(2.16) Up From $(2.90) YoY, Sales $12.650K Down From $44.031K YoY

Sep 28, 2026, 2:11 PM UTC · Primary ticker $ADXN

Addex Therapeutics reported a significant decrease in sales for Q2, down 71.27% year-over-year, alongside a reduction in per-share losses. The substantial drop in revenue indicates potential operational challenges or a decline in product demand, which is a major concern for investors.

Addex Therapeutics (ADXN) disclosed its Q2 earnings, revealing a dramatic 71.27% year-over-year decrease in sales, falling from $44.031 thousand to $12.650 thousand. While the company did narrow its per-share losses from $(2.90) to $(2.16), the substantial revenue decline is the dominant factor. This indicates a significant operational setback or reduced market penetration, which will likely lead to negative investor sentiment and pressure on the stock price in the short term. For traders, this presents a clear bearish signal, as the company's ability to generate revenue is severely impacted, raising questions about its long-term financial viability and growth prospects.

$ADXN negative Significant sales decline
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.